{"Title":"Avenue Therapeutics","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"3","Founded":"","Address":"","Phone":"(781) 652-4500","Web_address":"http://www.avenuetx.com","Market_cup":"$53.0mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-2.79 mil (last 12 months)","Symbol":"ATXI","Exchange":"NASDAQ","Shares":"5.5","Price_range":"$6.00 - $6.00","Est_volume":"$33.0 mil","Manager":"Oppenheimer","CO_managers":"National Securities Corp.","Exp_to_trade":"6/27/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain. Tramadol is a synthetic dual-acting opioid with a well-established efficacy and safety profile, and has been used throughout the world for more than 30 years, accumulating an abundance of available clinical data."}